Cancer Advisor

Executive Summary Cancer is increasingly recognized not only as a genetic disease but also as a metabolic disease . While genetic mutations drive tumor initiation and progression, metabolic reprogramming provides the fuel that allows cancer cells to survive, adapt, evade the immune system, and resist treatment. Over the past decade, metabolic oncology has evolved from a niche research field into one of the most promising frontiers in cancer treatment. However, many discussions remain polarized. Some portray cancer as purely a metabolic disease, while others dismiss metabolic interventions altogether. The scientific evidence suggests a more nuanced reality: Cancer is simultaneously a genetic, metabolic, immunological, and ecological disease. Successful treatment often requires addressing all of these dimensions systematically. This article prese...

Introduction: Why This Debate Matters Right Now The metabolic theory of cancer is exploding in popularity. Professor Tom Seyfried has become a household name among patients seeking alternatives to conventional oncology, thanks to his groundbreaking book Cancer as a Metabolic Disease and the press-pulse strategy built around glucose and glutamine restriction. But in May 2026, Jane McLelland —bestselling author of How to Starve Cancer and a stage 4 cancer survivor who reversed her own disease—published an interesting Substack titled “ Beyond Warburg: What Tom Seyfried Gets Right — And the Blind Spot That Could Cost Your Patient. ” This isn’t a takedown. It’s a respectful, evidence-based extension that could save lives by highlighting a critical limitation in the “keto-for-everyone” approach. If you’re exploring ketogenic diet cancer protocols, repurposed drugs, or metabolic therapies, this article breaks it all down with actionable insights into the metabolic theory of canc...

Introduction: The Promise and the Gap Metabolic therapy in oncology — encompassing ketogenic diets, caloric restriction, glucose-lowering drugs like metformin, and combinations thereof — has moved from fringe hypothesis to serious clinical inquiry over the past decade. Yet a fundamental question persists in both the research literature and the clinic: which patients actually respond? The answer is neither simple nor universal. Response to metabolic interventions appears to depend on tumor genetics, metabolic phenotype, immune context, and patient physiology. Understanding these variables is no longer optional for clinicians or researchers seeking to apply these approaches responsibly. This article reviews the current evidence on patient selection for metabolic therapy, identifies the biomarkers and tumor characteristics most associated with response, and highlights where the field still lacks clarity. What Is Metabolic Therapy in Cancer? Metabolic therapy refers to any intervention tha...

Abstract Background: Conventional metabolic oncology frameworks often group glucose-dependent and glutamine-dependent tumours under a singular "Warburg Effect" umbrella. However, distinct metabolic wiring requires precise patient selection to avoid off-target therapeutic failures. Methods: By analyzing substrate flux, PET tracer avidity ( 18 F-FDG vs. amino acid/glutamine tracers), and intracellular enzymatic expression, we constructed a 4-category classification matrix to guide adjunctive metabolic protocols alongside standard-of-care oncology. Results: Tumour bioenergetics stratify into four distinct phenotypes: Category 1: Glycolytic-Dependent (Glucose-Addicted); Category 2: Glutamine-Dependent (Glutaminolysis-Driven); Category 3: Hormone & Insulin-Driven; and Category 4: OxPhos-Reliant & Plastic Solid Tumours. Conclusion: Differentiating glucose addiction from glutamine addiction...

By The Medical Advisor Editorial Team | Last Updated: May 2026 Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Cancer treatment is highly individualized. Metabolic interventions can interact with chemotherapy, immunotherapy, or radiation and may cause harm if used improperly. Always consult your oncology team before adding any intervention. Evidence levels vary; many elements discussed remain investigational. Executive Summary Cancer is increasingly understood as more than a genetic disease. Dr. Thomas N. Seyfried , Professor of Biology at Boston College, and a growing body of metabolic oncology researchers propose that dysfunctional cellular energy production — centered on the mitochondria — is a defining and potentially modifiable axis of cancer biology. A 2026 large-scale population study published in Nature Communications demonstrated that machine learning-predicted insulin resistance was associated with increased risk of...